728 related articles for article (PubMed ID: 30191849)
1. Immune checkpoint inhibitors and cardiovascular toxicity.
Lyon AR; Yousaf N; Battisti NML; Moslehi J; Larkin J
Lancet Oncol; 2018 Sep; 19(9):e447-e458. PubMed ID: 30191849
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology.
Varricchi G; Galdiero MR; Tocchetti CG
Circulation; 2017 Nov; 136(21):1989-1992. PubMed ID: 29158212
[No Abstract] [Full Text] [Related]
3. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.
Escudier M; Cautela J; Malissen N; Ancedy Y; Orabona M; Pinto J; Monestier S; Grob JJ; Scemama U; Jacquier A; Lalevee N; Barraud J; Peyrol M; Laine M; Bonello L; Paganelli F; Cohen A; Barlesi F; Ederhy S; Thuny F
Circulation; 2017 Nov; 136(21):2085-2087. PubMed ID: 29158217
[No Abstract] [Full Text] [Related]
4. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.
Palaskas N; Lopez-Mattei J; Durand JB; Iliescu C; Deswal A
J Am Heart Assoc; 2020 Jan; 9(2):e013757. PubMed ID: 31960755
[No Abstract] [Full Text] [Related]
5. [Research progress on the immune checkpoint inhibitors induced cardiotoxicity].
Lyu SS; Yang YM
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Sep; 47(9):748-751. PubMed ID: 31550849
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology.
Chen DY; Huang WK; Chien-Chia Wu V; Chang WC; Chen JS; Chuang CK; Chu PH
J Formos Med Assoc; 2020 Oct; 119(10):1461-1475. PubMed ID: 31444018
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular toxicities associated with immune checkpoint inhibitors.
Hu JR; Florido R; Lipson EJ; Naidoo J; Ardehali R; Tocchetti CG; Lyon AR; Padera RF; Johnson DB; Moslehi J
Cardiovasc Res; 2019 Apr; 115(5):854-868. PubMed ID: 30715219
[TBL] [Abstract][Full Text] [Related]
8. Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Brown SA; Ray JC; Herrmann J
J Cardiovasc Transl Res; 2020 Jun; 13(3):402-416. PubMed ID: 32253744
[TBL] [Abstract][Full Text] [Related]
9. Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.
Guha A; Armanious M; Fradley MG
Trends Cardiovasc Med; 2019 Jan; 29(1):29-39. PubMed ID: 29910109
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.
Mir H; Alhussein M; Alrashidi S; Alzayer H; Alshatti A; Valettas N; Mukherjee SD; Nair V; Leong DP
Can J Cardiol; 2018 Aug; 34(8):1059-1068. PubMed ID: 29980467
[TBL] [Abstract][Full Text] [Related]
11. Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.
Ala CK; Klein AL; Moslehi JJ
Curr Cardiol Rep; 2019 Nov; 21(12):156. PubMed ID: 31768769
[TBL] [Abstract][Full Text] [Related]
12. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
13. Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies.
Biersmith MA; Tong MS; Guha A; Simonetti OP; Addison D
J Am Heart Assoc; 2020 Jan; 9(2):e013755. PubMed ID: 31960741
[No Abstract] [Full Text] [Related]
14. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.
Barroso-Sousa R; Ott PA; Hodi FS; Kaiser UB; Tolaney SM; Min L
Cancer; 2018 Mar; 124(6):1111-1121. PubMed ID: 29313945
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.
Wang GX; Kurra V; Gainor JF; Sullivan RJ; Flaherty KT; Lee SI; Fintelmann FJ
Radiographics; 2017; 37(7):2132-2144. PubMed ID: 29131763
[TBL] [Abstract][Full Text] [Related]
17. Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy.
Brumbaugh AD; Narurkar R; Parikh K; Fanucchi M; Frishman WH
Cardiol Rev; 2019; 27(2):97-107. PubMed ID: 29912044
[TBL] [Abstract][Full Text] [Related]
18. Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer.
Guenancia C; Ladoire S; Ghiringelli F; Rochette L; Vergely C; Cottin Y
Arch Cardiovasc Dis; 2017 Feb; 110(2):69-71. PubMed ID: 28216265
[No Abstract] [Full Text] [Related]
19. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.
Roviello G; Andre F; Venturini S; Pistilli B; Curigliano G; Cristofanilli M; Rosellini P; Generali D
Eur J Cancer; 2017 Nov; 86():257-265. PubMed ID: 29055841
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicities associated with immune checkpoint inhibitors.
Yang S; Asnani A
Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
